Tue, Mar 28, 2017 | updated 11:40 AM IST

Immunotherapy shows positive results in metastatic bladder cancer treatment

Updated: Oct 09, 2016 13:47 IST

WashingtonD.C. [USA], Oct. 9 (ANI): Immunotherapy has shown promising results in the first and

second line treatment of metastatic bladder cancer in two phase trials, a recent research

suggests.

Up to half of the patients with metastatic bladder cancer are not eligible for survival

prolonging first line treatment with cisplatin-based chemotherapy.

Survival in these patients is just nine to ten months with currently available alternative

chemotherapy.

The phase II KEYNOTE-052 trial1 evaluated the efficacy and safety of PD-1 blockade with

pembrolizumab as first line therapy in cisplatin ineligible patients with metastatic or locally

advanced bladder cancer.

The researchers presented the preliminary analysis of the first 100 patients enrolled in the

trial.

The primary endpoint of objective response rate was 24 percent.

The biomarker cut point to identify the patients, who are most likely to respond to the drug

was determined to be 10 percent or greater total PD-L1 expression in immune cells or tumor

cells.

Thirty patients had this level of expression of whom 11 (37 percent) responded to treatment.

The median duration of response has not yet been reached and treatment was well tolerated.

Lead author Arjun Balar, said: "Pembrolizumab has substantial activity with a favourable safety

profile as first line therapy in cisplatin ineligible patients with metastatic bladder cancer.

"The biomarker cut point will need to be validated in the larger study population, but seems to

identify patients most likely to respond to pembrolizumab well. Immunotherapy is rapidly

redefining our treatment approach for patients facing this dreadful disease," he added.

For several decades, there had been no global standard of care for second line treatment of

patients with metastatic bladder cancer who progress despite platinum-based chemotherapy until

the recent development of immune checkpoint blockade.

In another study, the phase II CheckMate 275 trial2 assessed the activity and safety of the

PD-1 inhibitor nivolumab in 270 patients with metastatic bladder cancer who have progressed

despite first line platinum-based chemotherapy.

CheckMate 275 is the largest study of a PD-1 inhibitor in bladder cancer reported to date.

In the 265 patients who could be evaluated for efficacy, the primary endpoint of objective

response rate was 19.6 percent.

The median duration of response has not yet been reached, with a median follow-up of seven

months.

In both patients with tumors expressing higher and lower levels of PD-L1 (including those with

less than 1 percent PD-L1), the objective response rate was above that achieved historically

with chemotherapy.

"This data is being submitted to support registration of nivolumab for patients with metastatic

urothelial cancer that has progressed despite platinum-based chemotherapy, an indication for

which the US Food and Drug Administration has granted breakthrough therapy designation to

nivolumab," said lead author Professor Matthew Galsky.

"Immune checkpoint blockade has become the most promising approach for these patients," he

added.

Commenting on the current management of bladder cancer, Maria De Santis, said, "There are

insufficient treatment options for patients ineligible for cisplatin and for those progressing

on cisplatin-based chemotherapy."

"This year the first immune check point inhibitor, atezolizumab, was approved for patients with

bladder cancer and CheckMate 275 provides similar results with nivolumab in the second line

setting," she said.

"KEYNOTE-052 confirms that immunotherapy is also active as first line therapy in cisplatin

ineligible patients, with a slightly lower response rate than chemotherapy. However, the

duration of response with pembrolizumab seems to exceed that of chemotherapy in historical

controls. The protocol included a new biomarker definition and cut-off which needs further

evaluation," said De Santis.

She concluded: "Immune check point inhibitors have started to alter the therapeutic landscape

for bladder cancer. We expect even more dramatic changes in the coming years with the use of

immunotherapy in other clinical stages and as combination therapy."

The study is presented in ESMO 2016. (ANI)

Washington D.C. [USA], Mar. 28 (ANI): Exposure to fungal product, called aflatoxin, is believed to cause up to 80 percent of liver cancer cases in many parts of the world.

Full Story >>

Washington D.C. [USA], Mar. 26 (ANI): Attention dog lovers! With just six months of training, a German Shepherd can accurately detect breast cancer, a study finds.

Full Story >>

Washington D.C. [USA], Mar. 26 (ANI): A recent study has found that a sleepless night impairs your ability to interpret subtle expressions of happiness and sadness.

Full Story >>

Washington D.C. [USA], Mar. 26 (ANI): When it comes to new moms' workout programs, less is more and so, according to a Kansas State University researcher, new moms may need a bit more flexibility and support to ease back into exercise after giving birth.

Full Story >>

New approach to diagnosing mental disorders

Updated: Mar 26, 2017 10:48 IST

Washington D.C. [USA], Mar. 26 (ANI): A consortium of psychiatrists and psychologists has proposed a new approach to diagnosing mental disorders.

Full Story >>

Washington D.C. [USA], Mar. 26 (ANI): Boosting natural brain opioids may be a better way to treat anxiety, according to a recent study.

Full Story >>

Fecal transplant offers hope for autistic kids

Updated: Mar 26, 2017 09:37 IST

Washington D.C. [USA], Mar. 26 (ANI): In this new era of medical therapy dawning, fecal transplants are poised to help fight a range of conditions, from deadly superbugs to obesity and now, autism is in the firing line.

Full Story >>

Thiruvallur (Chennai) [India], Mar. 25 (ANI): A highly contagious viral disease of cattle and swine, Foot-and-Mouth Disease (FMD) has affected Karani village on the outskirts of Tamil Nadu's Tiruvallur district.

Full Story >>

New Delhi [India], Mar. 25 (ANI): The findings of the National Family Health Survey 2015-16 confirm what we all knew from clinical evidence - that hypertension has become a major health concern among the Indian population, with as many as 22% Indians hypertensive.

Full Story >>

Washington D.C. [USA], Mar. 25 (ANI): A prescription weight-loss medication can decrease the urge to use opiates such as oxycodone, according to a recent study.

Full Story >>

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has discovered a new gene that is associated with Tau accumulation, which is one of the defining features of Alzheimer disease (AD).

Full Story >>

Washington D.C. [USA], Mar. 25 (ANI): All it takes is the flip of a protein "switch" within the tiny wire-like capillaries of the brain to increase the blood flow that ensures optimal brain function.

Full Story >>

Washington D.C. [USA], Mar. 25 (ANI): Scientists have found that stem cell therapy repairs damaged lungs - raising hopes of a cure for the crippling chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

Full Story >>

New method can cut dental implant failure

Updated: Mar 25, 2017 09:34 IST

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has come up with a new method to reduce dental implant failure.

Full Story >>

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has come up with a fluorogenic probe that can detect the activity of multidrug-resistant pathogens in an assay system.

Full Story >>

Virus hydrophobicity can help purify vaccines

Updated: Mar 25, 2017 07:46 IST

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has found that hydrophobic proteins on virus surfaces can help purify vaccines.

Full Story >>

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has shed light on why survivors of childhood brain tumours may be prone to heart disease, stroke, type 2 diabetes and early death.

Full Story >>

New Delhi [India], Mar. 24 (ANI): Continuing its efforts to raise awareness on tuberculosis and its diagnosis, Division of Clinical Microbiology & Molecular Medicine Department of Laboratory Medicine, AIIMS, and BD (Becton Dickinson India) for the third consecutive year organized a symposium today on "challenges in diagnosis and eradication of tuberculosis".

Full Story >>

New Delhi [India], Mar. 24 (ANI): On the solemn occasion of World Tuberculosis (TB) Day, Members of Parliament, policymakers, TB patients, survivors, and citizens of the civil society gathered at India Gate on Thursday, March 23 to pay tribute to the nearly five lakh lives lost due to this disease last year.

Full Story >>

New Delhi [India], Mar. 24 (ANI): Emergence of multi drug resistant TB and complications aggravated by high rates of co-infection with HIV-AIDS has renewed the threat of TB epidemic in India. With widespread prevalence of the infection, children experience a serious risk of contracting Tuberculosis, especially if they are under-nourished.

Full Story >>